HOME >> MEDICINE >> NEWS
Link between autism and abnormal blood-vessel function and oxidative stress

he time of the sample collection. These strict criteria resulted in the small sample size in this preliminary study: 26 children with autism and 12 healthy controls.

Pratico's team measured isoprostane, a biomarker for oxidative stress; thromboxane, an index of platelet activation; and prostacyclin, a measure of blood vessel activation in the samples. "This study represents the first observation that the rates of thromboxane and prostacyclin synthesis are both not only significantly increased in autism, but are closely correlated with the rate of oxidative stress," says Pratico. Compared with controls, children with autism had significantly higher urinary levels of isoprostane, thromboxone, and prostacyclin.

Oxidative stress is the result of an excessive formation of chemically unstable byproducts, called free radicals, within the cell. Under normal conditions, the cell is able to destroy the free radicals. However, when excessive free radicals accumulate, these molecules mount an attack against the cell in search of chemical stability.

"During oxidative stress, it is as if the free radicals have only one leg," explains Pratico. "They are searching for the second leg in order to keep from falling. Unfortunately, the ability of the excessive free radicals to reestablish their chemical equilibrium comes always with a price for the organ -- irreversible cellular and organ damage." Free radicals can damage cell membranes, proteins, and genes by oxidation -- the same chemical reaction that causes iron to rust.

Pratico and colleagues measured levels of isoprostane, the chemical byproduct of free radicals attacking fat cells and found that patients with autism possess nearly double the level of oxidative stress than that measured in healthy controls.

The samples from autistic patients also revealed a biochemical imbalance in the patients' blood vessels, resulting in high levels of thromboxane an indicator of platelet ac
'"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
15-Aug-2006


Page: 1 2 3

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Explaining a link between strokes and Alzheimers
3. Researchers call for investigation into links between khat use and psychiatric disorders
4. Comparison of patients access to new and better cancer drugs reveals inequalities between countries
5. No link found between autism and celiac disease
6. Research demonstrates link between domestic violence and asthma
7. Correlation between bile duct obstruction and ductal cancer found
8. Health gap between social groups widens in later life
9. Molecular differences between early and advanced melanomas could provide new drug targets
10. Queens studies find new links between wine, fermented foods and cancer
11. Link found between teens stress levels and acne severity

Post Your Comments:
(Date:5/29/2015)... Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... vulvar region and can cause significant physical, sexual, and ... major life altering disorder of Vulvodynia. The actual diagnosis ... Women’s Excellence in Endometriosis, they realize that this problem ... patient is experiencing any of these symptoms, they need ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 For the ... (USAU) to bring the Denver youth ultimate community an opportunity ... learning and individual improvement. The mission of the USAU Nike ... boys and girls to improve, build character, and make lifelong ... for boys and girls of all skill and ability levels, ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
(Date:5/29/2015)... An organizational consultant and part-time college professor, Dr. ... and may be suffering from early dementia. He is ... and in his uncertain relationship with his wife Addie. ... with corporate and government movers and shakers as they ... around him are being diagnosed with Alzheimer’s, Ben wonders ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Testosterone Centers of ... DFW area, is opening a new center in the Mid-Cities ... rest of the Mid Cities. Located on the south side ... in Hurst, the new testosterone center will open in May ... who suffer from low testosterone. , Like TCT’s other testosterone ...
Breaking Medicine News(10 mins):Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:‘Forgetful’ Professor Struggles With Dementia in Compelling New Novel 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "RNAi - ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... involves the use of double stranded RNA ... is processed into short 21-23 nucleotide RNAs ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
Cached News: